|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
12
|
|
pubmed:dateCreated |
2010-12-8
|
|
pubmed:abstractText |
It was postulated that in patients with membranous nephropathy (MN), four weekly doses of Rituximab (RTX) would result in more effective B cell depletion, a higher remission rate, and maintaining the same safety profile compared with patients treated with RTX dosed at 1 g every 2 weeks. This hypothesis was supported by previous pharmacokinetic (PK) analysis showing that RTX levels in the two-dose regimen were 50% lower compared with nonproteinuric patients, which could potentially result in undertreatment.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Dec
|
|
pubmed:issn |
1555-905X
|
|
pubmed:author |
pubmed-author:AbrahamRoshini SRS,
pubmed-author:BergstralhEric JEJ,
pubmed-author:CattranDaniel CDC,
pubmed-author:CosioFernando GFG,
pubmed-author:EirinAlfonsoA,
pubmed-author:EricksonStephen BSB,
pubmed-author:FervenzaFernando CFC,
pubmed-author:HicksonLaTonya JLJ,
pubmed-author:HoganMarie CMC,
pubmed-author:IrazabalMaria ValentinaMV,
pubmed-author:LeungNelsonN,
pubmed-author:LiXujianX,
pubmed-author:Mayo Nephrology Collaborative Group,
pubmed-author:NachmanPatrick HPH,
pubmed-author:RosenblatMM,
pubmed-author:SpecksUlrichU
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
5
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2188-98
|
|
pubmed:meshHeading |
pubmed-meshheading:20705965-Adult,
pubmed-meshheading:20705965-Aged,
pubmed-meshheading:20705965-Antibodies, Anti-Idiotypic,
pubmed-meshheading:20705965-Antibodies, Monoclonal, Murine-Derived,
pubmed-meshheading:20705965-Antigens, CD19,
pubmed-meshheading:20705965-B-Lymphocytes,
pubmed-meshheading:20705965-CD4-CD8 Ratio,
pubmed-meshheading:20705965-Female,
pubmed-meshheading:20705965-Glomerulonephritis, Membranous,
pubmed-meshheading:20705965-Humans,
pubmed-meshheading:20705965-Immunoglobulin G,
pubmed-meshheading:20705965-Immunosuppressive Agents,
pubmed-meshheading:20705965-Male,
pubmed-meshheading:20705965-Middle Aged,
pubmed-meshheading:20705965-T-Lymphocytes, Regulatory
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Rituximab therapy in idiopathic membranous nephropathy: a 2-year study.
|
|
pubmed:affiliation |
Division of Nephrology and Hypertension, Mayo Clinic College of Medicine, Rochester, MN 55901, USA. fervenza.fernando@mayo.edu
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Research Support, N.I.H., Extramural
|
